TABLE 1.
Clinical characteristics of all patients with relapsed/refractory diffuse large B‐cell lymphoma (R/R DLBCL) and separately by age ≤70 years and >70 years at relapse
| All R/R patients, n = 736 | Patients aged ≤70 years at relapse, n = 350 | Patients aged >70 years at relapse, n = 386 | |
|---|---|---|---|
| Sex | |||
| Men | 438 (60) | 211 (60) | 227 (59) |
| Women | 298 (40) | 139 (40) | 159 (41) |
| Age at relapse | |||
| ≤50 | 52 (7) | 52 (15) | – |
| 51–60 | 92 (12) | 92 (26) | – |
| 61–70 | 206 (28) | 206 (59) | – |
| 71–80 | 247 (34) | – | 247 (64) |
| >80 | 139 (19) | – | 139 (36) |
| Time to relapse | |||
| ≤6 months | 239 (32) a | 127 (36) | 112 (29) |
| >6–12 months | 218 (30) | 98 (28) | 120 (31) |
| >12–18 months | 84 (11) | 40 (11) | 44 (11) |
| >18–24 months | 53 (7) | 22 (6) | 31 (8) |
| >24 months | 142 (19) | 63 (18) | 79 (20) |
| Charlson Comorbidity Index (CCI) | |||
| 0 | 341 (46) | 204 (58) | 137 (36) |
| 1 | 122 (17) | 46 (13) | 76 (20) |
| 2+ | 273 (37) | 100 (29) | 173 (45) |
| LDH at relapse | |||
| Elevated | 330 (45) | 182 (52) | 148 (38) |
| Normal | 248 (34) | 104 (30) | 144 (37) |
| Missing | 158 (22) | 64 (18) | 94 (24) |
| Stage at relapse | |||
| I | 66 (9) | 28 (8) | 38 (10) |
| II | 98 (13) | 56 (16) | 42 (11) |
| III | 72 (10) | 37 (11) | 35 (9) |
| IV | 421 (57) | 199 (57) | 222 (58) |
| Missing | 79 (11) | 30 (9) | 49 (13) |
| Extranodal sites at relapse b | |||
| 0 | 310 (42) | 151 (43) | 159 (41) |
| 1 | 297 (40) | 136 (39) | 161 (42) |
| 2 or more | 128 (18) | 62 (18) | 66 (17) |
| Missing | 1 (0.0) | 1 (0.3) | 0 (0) |
| Performance status at relapse | |||
| 0 | 243 (33) | 128 (37) | 115 (30) |
| 1 | 289 (39) | 139 (40) | 150 (39) |
| 2 | 65 (9) | 30 (9) | 35 (9) |
| 3 | 32 (4) | 7 (2) | 25 (6) |
| 4 | 15 (2) | 6 (2) | 9 (2) |
| Missing | 92 (12) | 40 (11) | 52 (14) |
| IPI at relapse | |||
| 0 | 19 (2.6) | 19 (5.4) | 0 (0) |
| 1 | 89 (12.1) | 47 (13.4) | 42 (10.9) |
| 2 | 192 (26.1) | 95 (27.1) | 97 (25.1) |
| 3 | 179 (24.3) | 88 (25.1) | 91 (23.6) |
| 4 | 86 (11.7) | 30 (5.6) | 56 (14.5) |
| 5 | 9 (1.2) | 3 (0.9) | 6 (1.6) |
| Missing | 162 (22.0) | 68 (19.4) | 94 (24.4) |
| Molecular subtype | |||
| GCB | 278 (38) | 145 (41) | 133 (34) |
| Non‐GCB | 158 (22) | 85 (24) | 73 (19) |
| Unclassifiable/missing | 300 (41) | 120 (34) | 180 (47) |
| Second‐line treatment type | |||
| Intensive regimens | 255 (35) | 220 (63) | 35 (9) |
| DHAP/DHAO | 98 (38) | 90 (41) | 8 (23) |
| ICE | 89 (35) | 81 (37) | 8 (23) |
| GDP | 11 (4) | 8 (4) | 3 (9) |
| HD‐Mtx and/or HD‐AraC | 50 (20) | 37 (17) | 13 (37) |
| Other intensive | 7 (3) | 4 (2) | 3 (9) |
| Remission‐inducing regimens | 204 (28) | 64 (18) | 140 (36) |
| GemOx | 7 (3) | 1 (12) | 6 (4) |
| IME/MIME/IMVP‐16 | 109 (53) | 46 (72) | 63 (45) |
| Bendamustine | 51 (25) | 8 (12) | 43 (31) |
| CHOP | 21 (10) | 6 (9) | 15 (11) |
| VAdriaC | 10 (5) | 0 (0) | 10 (7) |
| Other remission‐inducing | 6 (3) | 3 (5) | 3 (2) |
| Palliative treatment | 147 (20) | 29 (8) | 118 (31) |
| Only radiotherapy | 76 (52) | 17 (59) | 59 (50) |
| Palliative IV chemotherapy | 26 (18) | 6 (21) | 20 (17) |
| Palliative oral chemotherapy | 45 (31) | 6 (21) | 39 (33) |
| No active treatment | 130 (18) | 37 (11) | 93 (24) |
| Immunotherapy c | |||
| Yes | 296 (40) | 142 (41) | 221 (57) |
| No | 363 (49) | 183 (52) | 113 (29) |
| Missing | 77 (10) | 25 (7) | 52 (14) |
Palliative IV chemotherapy included single‐agent regimens such as cyclophosphamide, gemcitabine or vinblastine. Palliative oral chemotherapy included mainly trophosphamide and chlorambucil. Proportions may add up to 99% or 101% due to rounding.
Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; DHAP/O, dexamethasone, high‐dose cytarabine, cisplatin/oxaliplatin; GCB, germinal centre B; GDP, gemcitabine, dexamethasone, cisplatin; GemOx, gemcitabine, oxaliplatin; HD‐Mtx and/or HD‐AraC, high‐dose methotrexate and/or high‐dose cytarabine; ICE, iphosphamide, carboplatin, etoposide; IME, iphosphamide, methotrexate, etoposide; IPI, International prognostic index; IV, intravenous; LDH, lactate dehydrogenase; VAdriaC, vincristine, doxorubicin, cyclophosphamide.
208 patients were primary refractory with stable or progressive disease as best response to primary therapy.
In the whole cohort 118 patients had involvement of the central nervous system at relapse.
A majority received rituximab, and three received ofatumumab.